CIK 0001124105
- Accelerated filer
- Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 562020050
- Phone
- +1 858-284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-08 | Luo Ying Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2026-05-06 | Luo Ying Chief Executive Officer | Sale 10b5-1 | −10,136 | $8.04 | $81K | 2,565,226 |
| 2026-05-05 | Luo Ying Chief Executive Officer | Sale 10b5-1 | −179 | $8.01 | $1K | 2,575,362 |
| 2024-08-14 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +26,000 | 26,000 | ||
| 2023-11-20 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +3,350,897 | 3,350,897 | ||
| 2023-11-20 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +2,262,755 | 2,262,755 | ||
| 2023-10-31 | Luo Ying Director | Grant or award · Stock Option (Right to Buy) | +1,866 | 1,866 | ||
| 2023-10-30 | Luo Ying Director | Other acquisition | +2,840,376 | 2,840,376 |
Page 1 of 1 · 8 trades